CONTEPO
Launchfosfomycin disodium
NDAINTRAVENOUSPOWDERPriority Review
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
CONTEPO (fosfomycin disodium) is [ see microbiology () ] . First approved in 2025.
Drug data last refreshed Yesterday
Mechanism of Action
[ see Microbiology () ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.